Sign up to save your podcasts
Or
Share Discussions about Cardiology from theheart.org: CURRENT-OASIS 7, CURE, ACTIVE A, and INNOVATE PCI: Exploring the world of antiplatelet therapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Discussions about Cardiology from theheart.org: CURRENT-OASIS 7, CURE, ACTIVE A, and INNOVATE PCI: Exploring the world of antiplatelet therapy
Results from the CURRENT-OASIS 7 study suggest that doubling the dose of clopidogrel for the first seven days in patients undergoing PCI is beneficial.
The CURE and ACTIVE A studies showed that loss-of-function CYP2C19 alleles did not have any effect with regard to safety or efficacy of clopidogrel in participating ACS and AF patients.
And yet another antiplatelet agent, elinogrel, passed initial safety and clinical hurdles in the INNOVATE PCI trial.
What does this mean for the future of antiplatelet therapy? Join Drs Keith Fox and Harvey White as they discuss the take-home messages from these and other important antiplatelet trials.
View all episodes
By theheart.org
3
22 ratings
Results from the CURRENT-OASIS 7 study suggest that doubling the dose of clopidogrel for the first seven days in patients undergoing PCI is beneficial.
The CURE and ACTIVE A studies showed that loss-of-function CYP2C19 alleles did not have any effect with regard to safety or efficacy of clopidogrel in participating ACS and AF patients.
And yet another antiplatelet agent, elinogrel, passed initial safety and clinical hurdles in the INNOVATE PCI trial.
What does this mean for the future of antiplatelet therapy? Join Drs Keith Fox and Harvey White as they discuss the take-home messages from these and other important antiplatelet trials.
More shows like Discussions about Cardiology from theheart.org
View all
This Week in Cardiology
862 Listeners